摘要
目的:观察EPO对慢性充血性心力衰竭(CHF)治疗效果。方法:选择CHF患者212例,随机分为非EPO治疗组(56例)和EPO治疗组(156例)。其中非EPO治疗组采用常规抗心衰治疗,EPO治疗组接受常规抗心衰治疗和EPO治疗,直至临床观察结束。治疗后观察心功能指标改变。结果:156例心衰患者经过EPO治疗后,左室射血分数,每搏输出量,每分输出量,心指数均较非EPO治疗对照组患者明显改善(P<0.05),其中尤以左室射血分数改善最为明显(P<0.01)。156例EPO治疗组患者中116例心衰伴贫血患者心功能各项指标的改善较40例心衰不伴贫血患者更为明显,具有显著统计学意义(P<0.01)。结论:EPO对CHF患者心功能的改善主要是因为EPO的促红细胞生成作用。EPO对于慢性心功能不全有独立于促红细胞生成以外的治疗作用。
Objective：To observe therapeutic efficacy of erythropoietin to patients with chronic congestive heart failure.Methods： 212 cases were randomly divided into Non-erythropoietin treatment group （n=56） and erythropoietin treatment group （n=156）. Non-erythropoietin treatment group received routine therapy,and erythropoietin treatment group received routine therapy and erythropoietin therapy till clinical observation termination.Heart function parameter alteration was observed.Results：Left ventricular ejection fraction,stroke volume,cardiac minute volume,cardiac index of patients in erythropoietin treatment group were obviously improved compared with those in non-erythropoietin group （P〈0.05）.Left ventricular ejection fraction was mostly improved （P〈0.01）. In erythropoietin treatment group,all parameters of 116 cases with anemia were obviously improved compared with those of 40 cases without anemia,having statistical significance （P〈0.01）.Conclusions：Hematopoiesis of erythropoietin plays an important part in improving function of chronic congestive heart failure amelioration.There are more therapeutical effects besides erythropoiesis of erythropoietin for treating chronic congestive heart failure.
出处
《现代生物医学进展》
CAS
2008年第11期2098-2099,2115,共3页
Progress in Modern Biomedicine
